Maxygen Financial Statements
Maxygen Financial Information
| Company Type | Public Headquarters |
|---|---|
| Fiscal Year-End | December |
© 2009 Morningstar, Inc. Financial Data provided by
Maxygen Income Statement
| 2008 | 2007 | 2006 | |
|---|---|---|---|
| Revenue ($ mil.) | 100.7 | 23.2 | 25.0 |
| Gross Profit ($ mil.) | -- | -- | -- |
| Operating Income ($ mil.) | -- | -- | -- |
| Total Net Income ($ mil.) | 30.3 | (49.3) | (16.5) |
| Diluted EPS (Net Income) | 0.81 | (1.34) | (0.46) |
Maxygen Quarterly Statements
| Quarter Ending Jun 09 | Quarter Ending Mar 09 | Quarter Ending Dec 08 | |
|---|---|---|---|
| Revenue ($ mil.) | 6.8 | 8.5 | 6.0 |
| Gross Profit ($ mil.) | -- | -- | -- |
| Operating Income ($ mil.) | -- | -- | -- |
| Total Net Income ($ mil.) | (5.9) | (1.1) | (7.7) |
| Diluted EPS (Net Income) | (0.15) | (0.03) | (0.21) |
Maxygen Stock Quote & Chart
11/06/09 16:00:01 EST •
NASDAQ •
5.70
•
 -0.1700
•
-2.8961 %
|
|---|
|
Quotes delayed 15 minutes for NASDAQ. 20 minutes for NYSE and AMEX. Market Data provided by Interactive Data. Powered and Implemented by Interactive Data Managed Solutions.
|
Maxygen Financial Ratios
| Company | Industry Median |
Market Median1 |
|
|---|---|---|---|
| Price/Sales Ratio | 1.96 | 7.49 | 7.00 |
| Price/Earnings Ratio | 3.41 | 92.59 | 25.45 |
| Price/Book Ratio | 1.17 | 3.46 | 6.74 |
| Price/Cash Flow Ratio | 2.91 | 41.15 | 43.48 |
1 Public companies trading on the New York Stock Exchange, the American Stock Exchange, and the NASDAQ National Market.
Detailed Maxygen Financial Ratios
Maxygen Competitive Intelligence
| Eli Lilly | Genentech | Human Genome Sciences | |
|---|---|---|---|
| Annual Sales ($ mil.) | 20,378.0 | 13,418.0 | 48.4 |
| Employees | 40,500 | 11,174 | 880 |
| Market Cap ($ mil.) | 39,560.8 | -- | 4,549.4 |
Competitive Landscape
